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Abstract
The vascular endothelial growth factor regulates angiogenesis that is increased in glioma. VEGF polymorphisms are
thought to modulate vascular endothelial growth factor plasma levels and therefore may be implicated in glioma risk. We
aimed to clarify the role of VEGF and von Willebrand factor polymorphisms in glioma susceptibility and prognosis. A
case–control study of 126 glioma patients and 180 cancer-free controls was performed. Using Sequenom MassARRAY
platform, 11 VEGF and 1 VWF polymorphisms were genotyped. Unconditional multivariate logistic regression models
were used to calculate odds ratios and 95% confidence intervals. The associations between polymorphisms and survival
were evaluated using a Cox regression model. Bonferroni’s adjustment was used to correct for multiple testing. The
VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblas-
toma (odds ratio = 155.66), confirmed after Bonferroni correction. Also, the VEGF polymorphisms rs3024994,
rs2010963, and particularly the homozygous carriers of rs1005230 were associated with a worse prognosis for glioma
and glioblastoma. Our data support a role of VEGF and VWF polymorphisms as glioma biomarkers, with additional poten-
tial relevance for molecular stratification of patients for anti-angiogenic therapies.
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Introduction
Gliomas are the most frequent primary malignant cen-
tral nervous system tumors.1–3 These tumors present a
multifactorial etiology, being the result of interactions
between environmental exposure and genetic suscept-
ibility.4 The only proven exogenous environmental
cause of glioma is ionizing radiation.5,6 Perhaps other
environmental causes are involved but remain to be
proven. Accordingly, the genetic polymorphisms most
frequently studied in the context of brain tumors are
located in genes that might influence susceptibility to
these tumors in concert with environmental exposures,
such as those involved in DNA repair, cell cycle regula-
tion, or immune response.7–12 In addition, few genome-
wide association studies have focused on gliomas
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identifying five risk loci for glioma mostly related to
telomerase.13–17
Common pathways in glioma biology include
growth factor receptor tyrosine kinases and their sig-
naling pathways. Polymorphisms on the epidermal
growth factor (EGF) and its receptor, EGFR, have
been identified as risk factors for glioma.17–19 In addi-
tion, vascular endothelial growth factor (VEGF) is the
principal angiogenic factor in both embryonic develop-
ment and tumor growth and is highly up-regulated in
glioblastoma, and its receptors are over-expressed in
tumor vessels.20 Importantly, the anti-angiogenic drug
bevacizumab, a humanized monoclonal immunoglobu-
lin (Ig) G1 antibody that binds to and inhibits the bio-
logical activity of human VEGFA, is currently being
explored in different clinical trials involving glioma and
has been used in combination with chemotherapy for
the treatment of recurrent glioblastoma,20–24 which
resulted in improved response rates and extended
progression-free survival (PFS). Recent studies have
shown that some single nucleotide polymorphisms
(SNPs) of VEGF/VEGF-related genes could contribute
to the modulation of serum VEGF levels, possibly
influencing risk and prognosis of solid tumors, includ-
ing glioma.25–27 Moreover, VEGF and VEGFR2 genetic
polymorphisms could predict not only patient out-
come, as shown by Sjostrom et al.,28 but also the
response to bevacizumab in glioblastoma patients.29
The von Willebrand factor (VWF) is an essential
component of hemostasis at sites of vascular injury.30
The VWF gene is highly polymorphic, and SNPs have
been found to influence the levels of VWF in the circu-
lation.31,32 Moreover, VWF SNPs were also associated
with lung cancer risk; however, susceptibility was
related with patients’ origin.33,34
Given the important role of VEGF signaling in glio-
mas and the influence tumor risk and prognosis of
particular VEGF/VEGFR polymorphisms in different
tumor types, we investigated the relevance of 11 genetic
polymorphisms in the 6p12 (VEGFA) and 6p21 (VWF)
loci on glioma risk and patient survival.
Materials and methods
Study population
In this case–control study, we enrolled 126 glioma sam-
ples from Hospital S. Joa˜o, Porto, and Hospital de
Braga, Braga, Portugal. Tumors were classified accord-
ing to the World Health Organization (WHO) criteria
(Table 1).1 All patients above 18 years of age, with diag-
nosis of glioma, treated between 2009 and 2010, and
that by informed consent accepted to participate in the
study, were included. The patients with different diag-
nosis or that refused to sign the informed consent were
excluded. Complete treatment data were retrieved for
90 patients. Of those, 80 patients underwent surgery, 9
stereotactic biopsy, 77 radiotherapy, 71 chemotherapy
(65 underwent Stupp protocol,35 7 surgery only,
8 surgery+ radiotherapy, 5 surgery+ radiotherapy+
chemotherapy (other than temozolomide), 2 surgery
+chemotherapy, and 2 biopsy only), and one addi-
tional patient refused treatment. The 180 control sam-
ples were selected from cancer-free blood donors at
Hospital de Braga, to match for gender and adjust for
age in the statistical analysis (Table 1). All patients and
controls had a Caucasian background and come from
the same region in the north of Portugal. The follow-up
information was obtained by consulting clinical records.
The control group had no follow-up information.
Signed informed consent was obtained from each parti-
cipant. Local institutional ethics committees of Hospital
S. Joa˜o and Hospital de Braga approved the procedures
followed in this study.
Table 1. Clinico-pathological features of gliomas and controls.
Groups (WHO grade) N Age, years
(median 6 SD)
p valuea M/F
ratio
p valuea PFS, months
(median)
OS, months
(median)
Controls 180 35–85 (53.0 6 10.8) p=0.003 1.69 p= 0.768 n.a. n.a.
Gliomas (2–4) 126 20–83 (58.0 6 12.7) 1.63 9 (1–48) 16.5 (1–52)
Astrocytic tumors (2–4) 101 22–83 (59.0 6 11.9) 1.97 9 (1–40) 16 (1–52)
Diffuse astrocytoma (2) 5 35–67 (41.0 6 13.5) 0.67 15.5 (9–22) 15.5 (9–22)
Anaplastic astrocytoma (3) 6 32–62 (47.0 6 12.2) 1.0 36 48
Glioblastoma (4) 86 22–83 (59.5 6 11.6) 2.07 9 (1–40) 15.5 (1–52)
Gliosarcoma (4) 4 50–72 (61.5 6 9.1) All M 5.5 (3–10) 22.5 (7–31)
Oligodendroglioma (2–3) 25 20–78 (50.0 6 14.1) 0.78 9 (3–48) 23 (6–48)
Oligodendroglioma (2) 7 20–58 (45 6 13.4) 0.4 48 40.5 (33–48)
Anaplastic oligodendroglioma (3) 18 23–78 (53 6 14.0) 1.0 8.5 (3–48) 22 (6–48)
WHO: World Health Organization; n.a.: not applicable; SD: standard deviation; M: male; F: female; OS: overall survival; PFS: progression-free
survival.
ap value for independent samples t-test, for testing differences in age and M/F ratio between controls and glioma.
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Genotyping
DNA was extracted from the leukocytes of blood sam-
ples using the commercially available Citogene Blood
Kit according to the manufacturer’s recommendations.
Genotyping of the allele-specific primer extension prod-
ucts, which were generated from amplified DNA
sequences, was performed using the Sequenom
MassARRAY iPLEX Gold platform (Sequenom, San
Diego, CA) at the Instituto Gulbenkian de Cieˆncia
(IGC), Lisbon, Portugal. Primers were designed using
MassARRAY Assay Design 3.1 software (Sequenom),
and genotyping was performed in a blinded manner
regarding sample status (i.e. case or control subjects).
The genotyping quality was assessed by duplicate anal-
ysis of 10% of the samples, which demonstrated a
100% agreement rate.
Statistical analysis
Independent samples t-test, x2 test, and nonparametric
Wilcoxon–Mann–Whitney test were used to compare
the frequency distribution of age, sex, and genotypes of
VEGF and VWF and the allele distribution among the
cases and controls. Moreover, the x2 test was used to
verify whether the observed allele distribution in the
control group was in Hardy–Weinberg equilibrium
(HWE). The odds ratio (OR) and 95% confidence
intervals (95% CIs) for the effect of the polymorphic
variants on the risk for glioma were estimated by multi-
variate logistic regression analysis, adjusted for gender
and age as a continuous variable. Bonferroni’s adjust-
ment was used to correct for multiple testing.
Associations between polymorphic variants and patient
survival were assessed using a multivariate Cox regres-
sion model adjusted for patient gender and age. All sta-
tistical tests were two-sided, and significance was
considered for p\ 0.05. Data analysis was performed
using IBM SPSS Statistics, version 20.0.
Results
Our cohort of samples included 126 glioma samples
(WHO grade II–IV) and 180 cancer-free controls
(Table 1). All studied variants were in HWE, apart
from the polymorphism rs3025035, for which it was
not possible to calculate due to the absence of the
homozygous recessive genotype.
Glioma risk assessment
In order to explore the associations between VEGF and
VWF variants and risk for glioma, we used an uncondi-
tional multivariate logistic regression analysis adjusted
for potential confounding variables (SNP genotypes,
patient age, and sex).
We could successfully include on the multivariate
logistic analysis 107 cases and 143 controls. The fre-
quencies of each genotype in controls and cases are pre-
sented in Table 2 for VEGF and VWF. The most
frequent allele was used to establish the reference geno-
type. The control group was compared with all glioma
cases (WHO grades 2–4), and also with glioblastoma
(WHO grade 4), and oligodendroglioma (WHO grades
2–3; Table 2), since these were the most frequent sub-
types in our series (Table 1).
We found a significant association between the
VEGF SNPs heterozygous rs833061 and risk for
glioma and glioblastoma (OR=164.85, 95% CI=
24.72–1099.54 and OR=155.66, 95% CI=17.29–
1401.69, respectively, p\ 0.001 and p\ 0.012 after
Bonferroni correction, Table 2), as well as the variant
carriers of this SNP had an increased glioma and glio-
blastoma risk (OR=116.54, 95% CI=20.59–659.69
and OR=87.73, 95% CI=12.96–593.67, respectively,
p\ 0.001 and p\ 0.012 after Bonferroni correction,
TT vs TC+CC). Also, the heterozygous rs3024994
was associated with increased risk for glioma
(OR=4.86, 95% CI=1.29–18.35, p=0.020, Table 2)
and glioblastoma (OR=6.36, 95% CI=1.31–30.83,
p=0.022, Table 2), and the rs25648 variant carriers
demonstrated an increased risk for oligodendroglioma
(OR=3.69, 95% CI=1.11–12.26, p=0.033, Table
2); however, the significance of these results was not
confirmed after Bonferroni correction (p. 0.05).
Regarding the VWF rs9295740 SNP, we observed a
significant association between the heterozygous geno-
type and risk for glioblastoma (OR=2.24, 95%
CI=1.00–4.98, p=0.049, Table 2); however, the sig-
nificance of this result was not confirmed after
Bonferroni correction (p. 0.05).
No statistically significant associations were found
between the VEGF SNPs rs3025035, rs3025039,
rs3025040, rs1005230, rs699947, rs833070, rs3025010,
and rs2010963 variants and risk for glioma, glioblas-
toma, or oligodendroglioma (Table 2; all p values
. 0.05).
Glioma prognostic assessment
In a subset of glioma patients, follow-up data were also
available (n=57). The PFS of the samples was
9months (1–48months), and the overall survival (OS)
was 16.5months (1–52months; Table 1). We interro-
gate the associations between each VEGF variant,
VWF, and PFS or OS by a multivariate Cox propor-
tional hazard model, adjusted for patient age and sex
(Table 3). The heterozygous rs3025035 was significantly
associated with improved PFS of glioma and glioblas-
toma (hazard ratio (HR)=0.15, 95% CI=0.03–0.73,
p=0.019 and HR=0.11, 95% CI=0.02–0.72,
p=0.021, respectively, Table 3). Improved PFS for
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glioma was also seen for the heterozygous rs3025010
and for the variant carriers of this SNP (HR=0.23,
95% CI=0.08–0.70, p=0.009 and HR=0.29, 95%
CI=0.11–0.78, p=0.015, respectively, Table 3). On
the other hand, glioma patients’ carriers of rs833061
variant (HR=12.59, 95% CI=1.19–38.55, p=0.035,
Table 3) and heterozygous or variant carriers of
rs3024994 (HR=6.52, 95% CI=1.38–30.82,
p=0.018 and HR=5.08, 95% CI=1.30–19.81,
p=0.019, respectively, for OS and HR=16.33, 95%
CI=2.79–95.43, p=0.002 and HR=6.17, 95%
CI=1.51–25.15, p=0.011, respectively, for PFS,
Table 3) had a decreased survival. However, after
Bonferroni correction, only the heterozygosity of
rs3024994 was found to be significantly associated with
decreased survival (p=0.024, after correction).
The rs1005230 homozygous carriers presented a
decreased OS and PFS both for glioma (OS:
HR=85.07, 95% CI=4.38–1654.35, p=0.003 and
p=0.036 after Bonferroni correction and PFS:
HR=65.72, 95% CI=3.00–1439.81, p=0.008 and
p=0.096 after Bonferroni correction, Table 3) and
glioblastoma patients (OS: HR=249.48, 95%
CI=8.84–7040.50, Figure 1(a) and PFS: HR=672.46,
95% CI=12.37–36,562.04, p\ 0.001 and p\ 0.012
after Bonferroni correction, Table 3). The heterozygous
genotype, has shown to confer an increased OS for glio-
blastoma patients (HR=0.02, 95% CI=0.00–0.75,
p=0.035, Table 3); however, not confirmed after
Bonferroni correction.
In addition, when only glioblastoma patients were
analyzed, we further observed a decreased survival for
rs699947 heterozygous (OS: HR=40.31, 95%
CI=1.07–1515.77, p=0.046 and PFS: HR=74.74,
95% CI=1.55–3594.07, p=0.029, Table 3), rs833061
heterozygous or variant carriers (OS: HR=11.94,
95% CI=1.04–137.51, p=0.047 and HR=16.08,
95% CI=1.35–191.51, p=0.028, respectively, and
PFS: HR=16.83, 95% CI=1.13–250.61, p=0.040,
Table 3); however, the significance of these results was
not confirmed after Bonferroni correction (p. 0.05).
The rs3024994 heterozygous or variant carriers (OS:
HR=7.89, 95% CI=1.22–51.19, p=0.03 and
HR=6.05, 95% CI=1.08–33.94, p=0.041, respec-
tively, and PFS: HR=176.32, 95% CI=8.58–
3622.74, p\ 0.001 and p\ 0.012 after Bonferroni cor-
rection, and HR=16.84, 95% CI=2.60–109.26,
p=0.003 and p=0.036 after Bonferroni correction,
Table 3) and rs2010963 heterozygous and variant
homozygous (OS: HR=11.16, 95% CI=2.12–58.79,
p=0.004 and p=0.048 after Bonferroni correction,
Figure 1(b) and PFS: HR=20.10, 95% CI=1.45–
279.11, p=0.025 and p=0.300 after Bonferroni cor-
rection, respectively, Table 3). Finally, rs3025010 var-
iant homozygous carriers had an improved OS for
glioblastoma (HR=0.04, 95% CI=0.002–0.63,
Figure 1. Survival graphs of significant associations between overall survival of glioblastoma patients and VEGF SNPs. Multivariate
Cox proportional hazard model regression with respect to glioblastoma patient survival of (a) rs1005230, hazard ratio
(HR) = 249.48; 95% confidence interval (CI) = 8.84–7040.50, p\0.001, for TT genotype and (b) rs2010963, HR= 11.16, 95%
CI = 2.12–58.79, p= 0.004.
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p=0.022 and p=0.264 after Bonferroni correction,
Table 3).
Discussion
VEGF is the major proangiogenic factor involved in
tumor growth and progression, including glioblastoma,
being over-expressed in tumor vessels.20 VEGF–
VEGFR signaling pathway stimulates not only angio-
genic signals but also the secretion of the VWF from
endothelial cells, and VWF was described as having a
potential role on angiogenesis.36–38 We have studied the
contribution of 11 VEGF and 1 VWF polymorphisms
to the risk and outcome of glioma and glioblastoma in
the Portuguese population. These polymorphisms were
selected based on some of the several studies that
reported that some SNPs in the VEGF and VWF loci
may conditionate serum VEGF expression modulation
and therefore confer tumor risk.25–27,34,39 These poly-
morphisms were reported to modify VEGFA serum
levels, in particular rs3025039 and rs2010963, and to
modulate risk, aggressiveness prognosis of different
solid tumors, specifically rs3025035, rs3025040,
rs699947, rs833061, rs833070, rs3025010, and
rs3024994.34,40–44 Moreover, anti-angiogenic therapies
are currently in clinical use for glioma patients, and
allelic variations of VEGF and VEGFR genes have
being associated with glioma patient responses to those
therapies.28
We found that, in our population, the VEGF
rs833061 SNP conferred an increased risk for glioma
and glioblastoma. Strikingly, rs833061 T/C heterozy-
gotes were over 150 times as likely to develop glioblas-
toma (OR=155.66, 95% CI=17.29–1401.69) or
glioma (WHO grade 2–4; OR=164.85, 95%
CI=24.72–1099.54). Although the physiological or
pathological function of the SNP rs833061 in glioblas-
toma is still unknown, this SNP has already shown to
be related to increased PFS in response to bevacizumab
in combination with sorafenib in recurrent glioblas-
toma patients.29
The rs3024994 C/T genotype presented an
OR=4.86 (95%CI=1.29–18.35) for glioma and
OR=6.36 (95% CI=1.31–30.83) for glioblastoma
and also the VWF rs9295749 SNP was associated with
an increased risk for glioblastoma; however, the signifi-
cance of this result was not confirmed after Bonferroni
correction (p. 0.05). Li et al.27 have reported that
rs3024994 variant was associated with a decreased risk,
whereas rs2010963 variant carriers and rs3025039 var-
iant homozygous had an increased risk for glioma.
Also Jiang et al.40 described rs3025039 and rs2010963
variant homozygosity to be associated with an
increased risk for glioma. These discrepancies could be
related to different background of the populations
studied. While the previous works have studied
Chinese patients, our samples are from Caucasian ori-
gin. Although no significant differences in genotype or
allele frequencies are observed between different popu-
lation origins,45 it was already reported for other dis-
eases that these polymorphisms differentially related to
risk in distinctive populations.46,47
Importantly, VEGF polymorphisms have been
related with patients’ response to anti-angiogenic drugs,
particularly bevacizumab.29,48 Few studies have
described an association between VEGF SNPs, specifi-
cally rs2010963, rs699947, rs833061, and rs1005230 and
response to bevacizumab in glioblastoma patients. In
particular, the rs2010963, rs699947, and rs833061 var-
iant homozygous genotypes were associated with an
increase in PFS, whereas the rs1005230 variant homozy-
gous genotype was associated with a decrease in PFS of
glioblastoma patients following bevacizumab treatment.
A major limitation of our study is the small number of
patients treated with bevacizumab (n=8), which did
not allow any statistical analysis to access the value of
the studied polymorphisms in the context of the bevaci-
zumab treatment. Therefore, we have also analyzed the
effect of these polymorphisms on patients’ survival,
independently of the treatment regimen applied.
The rs1005230 variant homozygous consistently pre-
sented a decreased OS and PFS both for glioma and
glioblastoma patients. Similarly, the rs3024994 variant
heterozygous consistently presented a decreased PFS
both for glioma and glioblastoma patients. Also the
rs2010963 heterozygous glioblastoma patients had a
reduced OS.
In conclusion, our data strongly suggest that differ-
ent VEGF SNPs highly increase the risk to develop
gliomas, and specifically glioblastoma, particularly the
presence of the rs833061 variant. Moreover, several
VEGF SNPs seem to be prognostic markers of glioma
and glioblastoma patients’ survival. In particular,
rs3024994 heterozygous and the homozygous carriers
of rs1005230 confer a worse prognosis for these
patients. Although these data need confirmation by
independent studies, they demonstrate that VEGF
SNPs are potential glioblastoma biomarkers.
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